文献速递炎症性肠病消化内镜

克罗恩病术后复发率及免疫抑制与生物制剂治疗的影响

Rates of Postoperative Recurrence of Crohn's Disease and Effects of Immunosuppressive and Biologic Therapies.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-04-06

该多中心回顾性队列纳入365例回结肠切除术后12个月内行回结肠镜的克罗恩病患者,中位随访88个月,48%出现临床术后复发,26%出现改良手术复发;Rutgeerts评分i2、i3、i4者无复发生存率低于i0/i1者。基于内镜结果启动免疫抑制或生物制剂治疗在i3/i4者中仅小幅降低临床复发风险,i2者未见获益。

要点

  • Rutgeerts评分i2-i4者术后临床与手术复发风险高于i0/i1者。
  • 内镜后启动免疫抑制或生物制剂在i3/i4者仅小幅降低临床复发风险。
  • 对无症状内镜复发且Rutgeerts评分为i2者,启动上述治疗未降低长期临床复发风险。

核心结论

  • 对无症状内镜术后复发的克罗恩病,用免疫抑制和TNF拮抗剂治疗未降低Rutgeerts i2者的长期临床复发风险,对i3或i4者仅有小幅效果。

研究设计与样本

  • 多中心回顾性队列,纳入2000至2013年比利时和法国2个中心365例回结肠切除吻合术后12个月内行回结肠镜的成人克罗恩病患者。
  • Rutgeerts评分分布:i0占20%,i1占10%,i2占49%,i3占12%,i4占9%;内镜后随访至少3年。

主要发现

  • 中位随访88个月,48%患者出现临床术后复发,26%出现改良手术复发。
  • Rutgeerts i2、i3或i4者无临床复发或改良手术复发的生存率低于i0或i1者(P < .001 和 P = .02)。
  • 内镜后启动新免疫抑制剂或生物制剂:i2/i3/i4组129/254例(51%),i0/i1组7/111例(6%),OR 14.9(95%CI 7.1-36.8;P < .001)。
  • 基于内镜结果启动免疫抑制或生物制剂后,i3或i4者临床复发风险小幅降低(Breslow P = .03),i2者未观察到(Breslow P = .46)。

临床怎么用

  • 术后内镜复查发现Rutgeerts i2的无症状患者,启动免疫抑制或生物制剂未必能降低长期临床复发风险。
  • Rutgeerts i3或i4患者基于内镜结果启动免疫抑制或生物制剂可能仅获得小幅临床复发风险下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The Rutgeerts' scoring system is used to evaluate patients with Crohn's disease (CD) following ileocolic resection, based on endoscopic findings at the anastomosis and in the neoterminal ileum. We investigated rates of clinical and surgical recurrence of CD after surgery and effect of therapy modification based on post-operative endoscopic findings. METHODS: We collected data from 365 adults with CD (20% with Rutgeerts' score i0, 10% with score i1, 49% with score i2, 12% with score i3, 9% with score i4) who underwent ileocolonoscopy within 12 months of ileocolic resection with anastomosis from 2000 through 2013 at 2 centers in Belgium and France. Patients were followed for 3 y or more after the ileocolonoscopy. Clinical post-operative recurrence (POR) was defined as occurrence of CD symptoms along with biologic, radiologic, and/or endoscopic features of disease activity; modified surgical POR was defined as either an endoscopic or surgical intervention. RESULTS: After a median follow-up time of 88 months, 48% of patients had clinical POR and 26% had modified surgical POR. Rates of survival without clinical POR or a modified surgical POR were lower in patients with Rutgeerts' scores of i2, i3, or i4 compared to patients with scores of i0 or i1 (P < .001 and P = .02). New immunosuppressant or biological therapy was initiated following endoscopy in 129/254 patients (51%) with Rutgeerts' score of i2, i3, or i4 vs 7/111 patients (6%) with scores of i0 or i1 (odds ratio for new therapy, 14.9; 95% CI, 7.1-36.8; P < .001). A modest decrease in risk of clinical POR was observed for patients with Rutgeerts scores of i3 or i4 after initiation of immunosuppressive or biological therapy based on endoscopic findings (Breslow P = .03), but this was not observed for patients with scores of i2 (Breslow P = .46). CONCLUSIONS: Use of immunosuppressants and tumor necrosis factor antagonists to treat patients with an asymptomatic endoscopic post-operative recurrence of CD did not reduce long-term risk of clinical recurrence in patients with Rutgeerts' scores of i2, but it had a small effect in patients with scores of i3 or i4.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Rivière P, Vermeire S, Irles-Depe M, et al. Rates of Postoperative Recurrence of Crohn's Disease and Effects of Immunosuppressive and Biologic Therapies. Clin Gastroenterol Hepatol. 2020. PMID: 32272248. doi:10.1016/j.cgh.2020.03.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。